StockNews.com downgraded shares of Fortress Biotech (NASDAQ:FBIO – Free Report) from a hold rating to a sell rating in a research note published on Thursday morning.
Other research analysts have also recently issued reports about the company. Roth Mkm reissued a buy rating and issued a $10.00 target price on shares of Fortress Biotech in a research note on Thursday, May 16th. HC Wainwright restated a buy rating and set a $24.00 price objective on shares of Fortress Biotech in a report on Friday, July 19th. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Fortress Biotech in a report on Thursday, June 20th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat, Fortress Biotech presently has a consensus rating of Moderate Buy and an average target price of $28.50.
View Our Latest Report on FBIO
Fortress Biotech Price Performance
Fortress Biotech (NASDAQ:FBIO – Get Free Report) last released its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.00. The firm had revenue of $13.03 million during the quarter, compared to analyst estimates of $14.33 million. As a group, equities analysts anticipate that Fortress Biotech will post -5.07 EPS for the current fiscal year.
Insider Activity
In other news, CEO Lindsay A. Md Rosenwald purchased 20,000 shares of the business’s stock in a transaction on Friday, June 28th. The stock was purchased at an average price of $1.64 per share, for a total transaction of $32,800.00. Following the completion of the purchase, the chief executive officer now directly owns 2,893,905 shares in the company, valued at approximately $4,746,004.20. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Lindsay A. Md Rosenwald purchased 20,000 shares of the business’s stock in a transaction on Friday, June 28th. The stock was purchased at an average price of $1.64 per share, for a total transaction of $32,800.00. Following the completion of the purchase, the chief executive officer now directly owns 2,893,905 shares in the company, valued at approximately $4,746,004.20. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Lindsay A. Md Rosenwald purchased 5,000 shares of the business’s stock in a transaction on Monday, July 8th. The stock was purchased at an average price of $7.35 per share, with a total value of $36,750.00. Following the purchase, the chief executive officer now owns 117,500 shares of the company’s stock, valued at $863,625. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 40,500 shares of company stock valued at $128,300. 33.40% of the stock is owned by insiders.
Hedge Funds Weigh In On Fortress Biotech
Several large investors have recently modified their holdings of FBIO. Armistice Capital LLC bought a new position in shares of Fortress Biotech in the fourth quarter valued at about $1,794,000. Acadian Asset Management LLC increased its position in Fortress Biotech by 124.3% during the first quarter. Acadian Asset Management LLC now owns 292,058 shares of the biopharmaceutical company’s stock worth $582,000 after acquiring an additional 161,870 shares during the period. PVG Asset Management Corp bought a new position in Fortress Biotech during the fourth quarter worth about $396,000. 180 Wealth Advisors LLC bought a new position in Fortress Biotech during the second quarter worth about $107,000. Finally, Shikiar Asset Management Inc. increased its position in Fortress Biotech by 21.8% during the first quarter. Shikiar Asset Management Inc. now owns 223,136 shares of the biopharmaceutical company’s stock worth $446,000 after acquiring an additional 40,000 shares during the period. 96.51% of the stock is owned by institutional investors.
About Fortress Biotech
Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.
Further Reading
- Five stocks we like better than Fortress Biotech
- What is Insider Trading? What You Can Learn from Insider Trading
- Chevron Stock Dips as Earnings Miss Highlights Merger Uncertainty
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- DraftKings Shares Fall After EPS Beat, Lower EBITDA Guidance
- How Investors Can Find the Best Cheap Dividend Stocks
- Investors Flock to Auto Retail Stock as It Hits New Highs
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.